Inotiv, Inc. Stock: price and management transactions · United States · SEC (Form 4)

About Inotiv, Inc.

Inotiv, Inc. is a U.S.-based company listed on the NASDAQ in the United States, and it operates as a contract research organization (CRO) focused on preclinical drug discovery and development support. Based on the company’s investor materials and latest annual filing, Inotiv provides nonclinical and analytical services to help pharmaceutical, biotechnology, medical device, academic, and government customers move programs through discovery and preclinical development, and in some cases into early clinical support. The company is headquartered in West Lafayette, Indiana, and traces its operating history back to 1975, when it began as Bioanalytical Systems, Inc.; it adopted the Inotiv name in March 2021. Inotiv’s business is organized into two reportable segments. Discovery and Safety Assessment (DSA) covers discovery and translational sciences, safety assessment, toxicology, pathology, analytical chemistry, surgery, and related preclinical services. Research Models and Services (RMS) supplies purpose-bred animal research models, specialized disease models, and associated products such as diets, bedding, and enrichment items. This gives Inotiv a hybrid profile: one part scientific services provider, one part research-model supplier. That structure can be attractive to customers seeking an integrated preclinical partner, while also making the business sensitive to pharma and biotech R&D spending cycles, utilization trends, and regulatory standards governing animal research and nonclinical studies. From a competitive standpoint, Inotiv occupies a specialist position in a fragmented CRO market that includes larger global competitors. Its scale is smaller than the industry giants, but it emphasizes technical depth in preclinical services and differentiated research models. The company’s value proposition is centered on helping customers improve data quality, shorten development timelines, and lower the cost of bringing new drugs and medical devices to market. For investors, that means the thesis depends on execution, specialization, and the ability to sustain demand across both services and research models. Recent developments have been important for the investment case. Inotiv reported fiscal 2025 revenue of $513.0 million, up 4.5% year over year, alongside a meaningful improvement in operating loss, although the company still reported a net loss. Management also disclosed a cybersecurity incident that began in early August 2025, with the forensic investigation completed by the time of the fiscal 2025 results update and operational and financial impacts still being assessed. The incident temporarily disrupted certain systems and internal processes, making cybersecurity resilience a relevant issue for ongoing monitoring. Overall, Inotiv remains a niche, science-driven CRO with a meaningful footprint in preclinical outsourcing, but investors should balance its growth potential against leverage, execution risk, and the operational risks highlighted by the 2025 cyber event.